Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018

SELL
$14.63 - $19.19 $498,166 - $653,438
-34,051 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$16.06 - $25.35 $546,859 - $863,192
34,051 New
34,051 $553,000

Others Institutions Holding GLYC

About GLYCOMIMETICS INC


  • Ticker GLYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,423,900
  • Market Cap $16.3M
  • Description
  • GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...
More about GLYC
Track This Portfolio

Track Clearbridge Investments, LLC Portfolio

Follow Clearbridge Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearbridge Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearbridge Investments, LLC with notifications on news.